Literature DB >> 6849784

Disposition of chloroquine in man after single intravenous and oral doses.

L L Gustafsson, O Walker, G Alván, B Beermann, F Estevez, L Gleisner, B Lindström, F Sjöqvist.   

Abstract

1 Chloroquine was given in 300 mg single doses as an i.v. infusion, an oral solution and as tablets at intervals of at least 56 days to 11 healthy volunteers. Concentrations of chloroquine and its metabolite desethylchloroquine were measured in plasma, erythrocytes and urine using h.p.l.c. 2 Chloroquine was detectable in all plasma samples up to 23 days and occasionally up to 52 days after dosage. Urinary concentrations were monitored up to 119 days. The disposition pattern was multiexponential reflecting extensive tissue binding of the drug. 3 After i.v. dosing the volume of distribution ranged from 116 to 285 l/kg and the apparent terminal half-life from 146 to 333 h. Total plasma clearance +/- s.d. was 712 +/- 166 ml/min and renal clearance 412 +/- 139 ml/min. The mean estimated urinary recovery of chloroquine was 47%, 42% and 46% after i.v., oral solution and tablets indicating nearly complete bioavailability. The corresponding figures for the metabolite were 7%, 10% and 12%. 4 The disposition of chloroquine in erythrocytes was parallel to that in plasma. The concentrations in erythrocytes were consistently 2 to 5 times higher than in plasma. 5 Subjective side effects like difficulties with swallowing and accommodation, diplopia and fatigue occurred during intravenous infusion and were closely related to plasma concentrations. No effect was seen on the electrocardiogram, mean arterial blood pressure and pulse rate. No adverse reactions were observed after the oral doses. High frequency audiometry did not reveal any significant hearing impairment for the group as a whole.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6849784      PMCID: PMC1427807          DOI: 10.1111/j.1365-2125.1983.tb01532.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Comparative bioavailabilities from truncated blood level curves.

Authors:  E G Lovering; I J McGilveray; I McMillan; W Tostowaryk
Journal:  J Pharm Sci       Date:  1975-09       Impact factor: 3.534

2.  THE OTOTOXICITY OF CHLOROQUINE PHOSPHATE.

Authors:  C W HART; R F NAUNTON
Journal:  Arch Otolaryngol       Date:  1964-10

3.  Improved fluorimetric assay of chloroquine in biological samples.

Authors:  S A Adelusi; L A Salako
Journal:  J Pharm Pharmacol       Date:  1980-10       Impact factor: 3.765

4.  Ototoxicity of chloroquine phosphate. A case report.

Authors:  G S Dwivedi; Y N Mehra
Journal:  J Laryngol Otol       Date:  1978-08       Impact factor: 1.469

5.  Determination of chloroquine and its desethyl metabolite in plasma, red blood cells and urine by liquid chromatography.

Authors:  G Alván; L Ekman; B Lindström
Journal:  J Chromatogr       Date:  1982-04-16

6.  The metabolism of chloroquine in man during and after repeated oral dosage.

Authors:  E W McChesney; M J Fasco; W F Banks
Journal:  J Pharmacol Exp Ther       Date:  1967-11       Impact factor: 4.030

7.  Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics.

Authors:  M Frisk-Holmberg; Y Bergkvist; B Domeij-Nyberg; L Hellström; F Jansson
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

8.  Distribution of chloroquine and its metabolite desethyl-chloroquine in human blood cells and its implication for the quantitative determination of these compounds in serum and plasma.

Authors:  Y Bergqvist; B Domeij-Nyberg
Journal:  J Chromatogr       Date:  1983-01-14
  8 in total
  89 in total

1.  Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine.

Authors:  Fabian Müller; Jörg König; Hartmut Glaeser; Ingrid Schmidt; Oliver Zolk; Martin F Fromm; Renke Maas
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  Is chloroquine making a comeback?

Authors:  Carla Cerami Hand; Steven R Meshnick
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions.

Authors:  Khondoker Alam; Sonia Pahwa; Xueying Wang; Pengyue Zhang; Kai Ding; Alaa H Abuznait; Lang Li; Wei Yue
Journal:  Mol Pharm       Date:  2016-02-01       Impact factor: 4.939

4.  Pharmacokinetics of intramuscular amopyroquin in healthy subjects and determination of a therapeutic regimen for Plasmodium falciparum malaria.

Authors:  F Verdier; E Pussard; F Clavier; J Le Bras; C Gaudebout
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

5.  Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain.

Authors:  P Donatelli; G Marchi; L Giuliani; L L Gustafsson; G M Pacifici
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro.

Authors:  M T Labro; C Babin-Chevaye
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

8.  Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum.

Authors:  Peter Starzengruber; Gunther Wernsdorfer; Maria Parizek; Chaiporn Rojanawatsirivet; Herwig Kollaritsch; Walther H Wernsdorfer
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

9.  Chloroquine excretion following malaria prophylaxis.

Authors:  L L Gustafsson; B Lindström; A Grahnén; G Alván
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

10.  Chloroquine in malaria. Isn't it time for revision of prophylaxis schedules?

Authors:  M Frisk; G Gunnert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.